Association between reported statin use at baseline and institutionalisation and death
| Categorisation of statin use | Unadjusted HR (95% CI) (n=1665) | Adjusted HR (95% CI)* (n=1497) | ||
|---|---|---|---|---|
| Institutionalisation | Death | Institutionalisation | Death | |
| Statin exposure | ||||
| Non-users† | 1.00 | 1.00 | 1.00 | 1.00 |
| Users | 0.90 (0.63 to 1.27) | 0.93 (0.75 to 1.15) | 1.60 (0.98 to 2.63) | 0.88 (0.66 to 1.18) |
| Duration of statin use | ||||
| Non-users | 1.00 | 1.00 | 1.00 | 1.00 |
| 0–<4 years | 1.10 (0.71 to 1.68) | 0.87 (0.65 to 1.16) | 1.73 (0.97 to 3.10) | 0.76 (0.53 to 1.09) |
| ≥4 years | 0.73 (0.46 to 1.17) | 0.97 (0.75 to 1.25) | 1.48 (0.82 to 2.68) | 0.99 (0.71 to 1.37) |
| Standardised daily dose‡ | ||||
| Non-users | 1.00 | 1.00 | 1.00 | 1.00 |
| Low | 0.77 (0.47 to 1.25) | 0.98 (0.75 to 1.29) | 1.25 (0.69 to 2.28) | 0.92 (0.66 to 1.29) |
| Medium | 1.01 (0.61 to 1.66) | 0.97 (0.71 to 1.33) | 2.00 (1.02 to 3.93) | 0.95 (0.65 to 1.40) |
| High | 1.00 (0.55 to 1.84) | 0.73 (0.48 to 1.12) | 2.45 (1.12 to 5.33) | 0.65 (0.40 to 1.07) |
*Adjusted for age, education, marital status, alcohol use, smoking, body mass index, self-reported comorbidities, self-reported cardiovascular diseases, impaired vision, depression, cognitive impairment, functional status, self-rated health, polypharmacy and for total cholesterol, high-density lipoprotein cholesterol and triglyceride concentrations.
†Non-users, the reference group.
‡Standardised daily dose was defined as follows: one unit of equivalent dose was based on a lipid-lowering effect of 10 mg of atorvastatin (fluvastatin 80 mg, lovastatin 40 mg, pravastatin 40 mg, simvastatin 2 mg, rosuvastatin 5 mg).18 19 Low dose was defined as <2 standardised unit, medium dose as 2–4 standardised unit, and high dose as ≥4 standardised unit.